BOEHRINGER-INGELHEIM
12.8.2020 14:38:12 CEST | Business Wire | Press release
Boehringer Ingelheim today announced that the first patient has enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents between six and 17 years old with clinically significant fibrosing interstitial lung disease (ILD).
Childhood ILD (chILD) includes more than 200 rare respiratory disorders that can affect infants, children and adolescents, making it difficult for them to breathe. In some cases, fibrosis which involves scarring and damage to the lungs can develop. This can lead to a significant impact on the daily life of those affected, as well as their families, including high morbidity and mortality. There are currently no approved therapies available for the treatment of chILD.
“Some children with interstitial lung disease may develop serious fibrosis that progresses,” said the coordinating investigator Prof. Robin Deterding, M.D., Director of the Breathing Institute, Children's Hospital Colorado. “Though the underlying causes of pulmonary fibrosis may be different in children, we’re excited to determine if treating the mechanism of fibrosis improves children’s lung fibrosis as it does in adults.”
Nintedanib, which is marketed as Ofev® , is currently approved in more than 80 countries for the treatment of people living with idiopathic pulmonary fibrosis (IPF).4 It is also approved in more than 40 countries as the first and only therapy to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD (SSc-ILD).5 Ofev® recently also obtained approval in the USA, Canada, Japan, Brazil, Argentina and the EU, for a third indication, as the first and only treatment for patients living with chronic fibrosing ILDs with a progressive phenotype.2,3
“Boehringer Ingelheim is proud to start this trial to provide valuable insights as we evaluate this potential treatment for children and adolescents with these rare and heterogenous conditions for which there are currently no treatments with proven efficacy and no randomized controlled trials,” said Dr Susanne Stowasser, Associate Head of Medicine Pulmonology at Boehringer Ingelheim. “This study represents our ongoing commitment to address unmet needs and advance research for adult and pediatric patients living with pulmonary fibrosis.”
~ENDS~
For references and notes to editors, please visit: http://www.boehringer-ingelheim.com/press-release/inpedildtrialenrollment
View source version on businesswire.com: https://www.businesswire.com/news/home/20200812005420/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Arcesium Acquires Limina to Deliver a Unified Front-to-Back Investment Platform2.2.2026 15:00:00 CET | Press release
Acquisition of P/OMS provider Limina answers industry’s need for a connected platform powering every stage of the investment lifecycle with advanced data, operations and analytics Arcesium, a leading global financial technology provider to the investment industry, today announces its acquisition of Stockholm-based portfolio and order management (P/OMS) systems provider, Limina, creating a full front-to-back operating platform tailored to the unique needs of asset managers, hedge funds and asset owners. Through the integration of Limina’s P/OMS with Arcesium’s middle- and back-office solutions, the combined offering will be designed to eliminate legacy fragmentation and connect siloed data, providing investment managers with the speed and insight they need to operate intelligently across asset classes and global markets. The entire Limina team will join Arcesium and play a key role in ongoing product development, advancing Arcesium’s commitment to optimizing the pre- and post -investmen
KiddeFenwal Launches New Line of Gas Ignition Controls for European and APAC Markets2.2.2026 15:00:00 CET | Press release
35-2X Series provides OEMs with increased reliability and customizable features, such as enhanced LED Diagnostics for troubleshooting, specifically for 230 VAC applications in HVAC, agriculture, pool heating, commercial cooking and more. KiddeFenwal, the global leader in the fire suppression and safety controls industry, today introduces its 35-2X Series, a new line of direct spark gas ignition controls for original equipment manufacturers (OEMs) in and serving European and Asia-Pacific markets. The series delivers highest quality gas ignition and safety modules supporting 230 VAC applications. The launch marks the next phase of KiddeFenwal’s global growth in the safety controls space, expanding its reach in Europe, Asia and Australia while building on its established North American presence. The company is offering the 35-2X Series via its trusted Fenwal Controls brand, which has served OEMs with reliable products and expert technical advice since 1935. “KiddeFenwal continues to bring
Klarna Backs Google’s Universal Commerce Protocol (UCP) to Enable Agentic Commerce Across Platforms2.2.2026 14:30:00 CET | Press release
Klarna, the global digital bank and flexible payments provider, is joining Google's Universal Commerce Protocol (UCP), an open standard designed to help AI agents and commerce systems work together across the full shopping lifecycle, from discovery and purchase through post-purchase support. UCP enables consumers to shop seamlessly in AI conversations while giving agents, merchant systems, and payment providers a standardized way to interact across multiple AI platforms. The announcement builds on Klarna’s recent support for Google’s Agent Payments Protocol (AP2) and expands Klarna's multiyear partnership with Google across Google Pay, Google Store, Google Play, and Google Cloud infrastructure. Together, these efforts reflect ongoing collaboration to support open standards as AI increasingly shapes how consumers shop online. “As AI-driven shopping continues to evolve, it’s important that the underlying commerce infrastructure is built on openness, trust, and transparency,” said David S
Tastepoint by IFF Predicts Ten Flavor Trends for 20262.2.2026 14:15:00 CET | Press release
From cherry to chai spice, Tastepoint’s trend experts reveal ten flavors poised to stand out this year. Tastepoint by IFF (NYSE: IFF), a leader in innovative flavor creations and taste solutions, has identified ten flavors expected to shape the North American food and beverage landscape in 2026. These predictions spotlight flavors anticipated to trend in retail, food service and beyond throughout the coming year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260202440399/en/ Flavors featured in Tastepoint by IFF's 2026 trend list. “To continue delivering product development solutions that meet consumers’ unique and changing needs, we stay attuned to industry and market trends, keeping a pulse on what’s relevant now and in the future,” said Nicole Potash, Tastepoint general manager. “Our annual flavor trend predictions reflect a vibrant mix of influences, from nostalgia-driven classics to global favorites gaining momentum in
AdvanCell Announces Collaboration and Exclusive Licensing Agreement with 48Hour Discovery to Develop a Novel Peptide-Based Lead-212 Radiotherapeutic for a Gastrointestinal Cancer with Significant Medical Need2.2.2026 13:30:00 CET | Press release
AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced that it has entered into a Collaboration and Exclusive Licensing Agreement with 48Hour Discovery to develop a novel peptide-based Lead-212 (212Pb) radiotherapeutic with an initial focus on a gastrointestinal cancer with significant medical need, reflecting AdvanCell’s strategy to build a durable pipeline of differentiated targeted alpha therapies addressing large oncology markets. The collaboration brings together 48Hour Discovery’s peptide discovery platform and AdvanCell’s 212Pb expertise to rapidly construct and advance a peptide-based radiotherapeutic program. Leveraging AdvanCell’s scalable 212Pb platform, which integrates secure isotope supply and modular manufacturing with deep expertise in developing 212Pb radioligand therapies, the program is designed to enable a rapid, repeatable path into the clinic and support the expansion of AdvanCell’s target
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom